Our Programs


We have leveraged our deep understanding of the emerging biology underlying endocrinology and hormone regulation to build a broad clinical pipeline. We are currently advancing the development of novel, potentially first-in-class, orally available treatments for endocrine diseases caused by hormone dysregulation where few or no approved medications exist.

  • MLE4901 is a neurokinin 3 receptor (NK3R) antagonist being developed for polycystic ovary syndrome (PCOS) and vasomotor symptoms (VMS).
  • ATR-101 is an acyl-CoA: cholesterol acyltransferase 1 (ACAT1) inhibitor being investigated in three orphan adrenal indications.